Altered Urothelial ATP Signaling in Major Subset of Human Overactive Bladder Patients with Pyuria

Alberto Contreras-Sanz\textsuperscript{1*}, Louise Krska\textsuperscript{1*}, Aswini A. Balachandran\textsuperscript{2}, Natasha L. Curtiss\textsuperscript{2}, Rajvinder Khasriya\textsuperscript{3}, Stephen Kelley\textsuperscript{1}, Matthew Strutt\textsuperscript{4}, Hardyal S. Gill\textsuperscript{5}, Kevin M. Taylor\textsuperscript{5}, Kylie J. Mansfield\textsuperscript{6}, Changhao Wu\textsuperscript{7}, Claire M. Peppiatt-Wildman\textsuperscript{1}, James Malone-Lee\textsuperscript{3}, Jonathan Duckett\textsuperscript{2}, Scott S. Wildman\textsuperscript{1}

\textsuperscript{1}Medway School of Pharmacy, Universities of Kent and Greenwich, Kent, UK; \textsuperscript{2}Obstetrics and Urogynaecology, Medway Maritime Hospital, Kent, UK; \textsuperscript{3}Division of Medicine, UCL Medical School, London, UK; \textsuperscript{4}Department of Microbiology, East Kent Hospitals University Foundation Trust, Kent, UK; \textsuperscript{5}Department of Pharmaceutics, UCL School of Pharmacy, London, UK; \textsuperscript{6}School of Medicine, University of Wollongong, NSW, Australia; \textsuperscript{7}Faculty of Health and Medical Sciences, University of Surrey, Surrey, UK; *Joint first authors.

Author for correspondence: Dr Scott S. Wildman PhD, Urinary System Physiology Unit, Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB; Tel: +44 (0)1634 202944; Fax: +44 (0)1634 883927; E-mail: s.s.wildman@kent.ac.uk
Abstract (200 words):

Overactive Bladder (OAB) is an idiopathic condition, characterized by urgency, urinary frequency and urgency incontinence, in the absence of routinely traceable urinary infection. We have described microscopic pyuria (≥10 wbc μl⁻¹) in patients suffering from the worst symptoms. It is established that inflammation is associated with increased ATP release from epithelial cells, and extracellular ATP originating from the urothelium following increased hydrostatic pressure, is a mediator of bladder sensation. Here, using bladder-biopsy samples, we have investigated urothelial ATP signaling in OAB patients with microscopic pyuria.

Basal, but not stretch-evoked, release of ATP was significantly greater from urothelium of OAB patients with pyuria than from non-OAB patients or OAB patients without pyuria (<10 wbc μl⁻¹). Basal ATP release from urothelium of OAB patients with pyuria was inhibited by the P2 receptor antagonist suramin and abolished by the hemichannel blocker carbenoxolone, which differed from stretch-activated ATP release. Altered P2 receptor expression was evident in urothelium from pyuric OAB patients. Furthermore, intracellular bacteria were visualized in shed urothelial cells from ~80% of OAB patients with pyuria.

These data suggest that increased ATP release from the urothelium, involving bacterial colonization, may play a role in the heightened symptoms associated with pyuric OAB patients.
**Introduction:**

Overactive bladder syndrome (OAB) is an idiopathic condition where the bladder detrusor urinae muscle spontaneously contracts before the bladder is full. In the USA, it is ranked in the top 10 of common chronic conditions, competing with both diabetes and depression, with a reported prevalence of up to 31-42% in the adult population (2).

OAB is currently characterized by symptoms of urgency, with or without urgency incontinence, with increased frequency, and nocturia, and in some cases pain, in the absence of urinary tract infection (UTI) or other defined underlying pathology (54). The exclusion of infection is determined by failure to isolate $\geq 10^5$ colony forming units (CFU)/ml of a single species of bacteria from culture of a midstream urine (MSU) specimen (23) and negative leukocyte esterase and/or nitrate urinalysis by dipstick (25). Controversy exists as to whether current methods used to determine UTI are fully accurate (28). It has been established that the bacterial threshold of $\geq 10^5$ CFU/ml, in the presence of symptoms, is not identified in approximately 50% of UTI (31). In addition, we have recently reported the low sensitivity and specificity of routine urinary dipstick tests (20, 51). Interestingly, in recent studies where the threshold has been reduced to $\geq 10^2$ CFU/ml, bacterial cystitis has been identified in approximately one third of patients with refractory OAB, suggesting bacteria may play a significant role in the aetiology of OAB, in at least a subset of patients with OAB (22, 37, 49). It is generally accepted, that the best indicator of UTI is the detection of $\geq 10$ white blood cells (wbc) in 1 µl of fresh, un-spun, urine examined using a haemocytometer (16, 44); however nowadays this is not normal clinical practice. Using this methodology, we have identified a low-grade inflammatory response (pyuria with $\geq 10$ wbc µl$^{-1}$) in 10-35% of MSU specimens from patients with OAB (i.e. symptoms of urgency, with or without urgency incontinence, with frequency and nocturia, in the absence of UTI) (45, and new data not shown). Interestingly, our observation is that these patients showed the worst symptoms of frequency. Most apposite to this finding is that persistent inflammation, caused by infection and thereby accompanied by pyuria, is associated with increased nucleotide (primarily adenosine 5'-triphosphate [ATP]) release from epithelial cells and nucleotide-activated P2 receptor signaling (4, 5, 36, 55).
Extracellular nucleotide signaling via P2 receptor activation is important in the regulation of bladder function (3, 7, 8). Bladder stretch, during filling, induces a cytosolic Ca\(^{2+}\) increase via multiple proposed pathways (9) to promote release of ATP through conductive or vesicular pathways (46), and probably other nucleotides from superficial urothelium. Once released, nucleotides bind to P2 receptors on suburothelial sensory afferents (P2X2, 3 and/or 2/3 subtypes) to trigger nerve activation and the sensation of bladder fullness and the urge to urinate (52). Given the rapid breakdown of extracellular nucleotides by nucleotidases, this route should involve intermediate signaling steps involving activation of P2 receptors on other urothelial cells to release additional nucleotides to act in an autocrine/paracrine manner (17, 19, 48, 58). Nucleotide signaling in human urothelium is enhanced in interstitial cystitis (IC) in humans and felines (17, 58), a condition symptomatically similar to OAB yet with the presence of pain and an inflammatory aetiology. In IC, stretch-activated ATP release is significantly increased, P2R expression profiles are altered in the urothelium, and ATP breakdown is purportedly decreased (15, 58).

Interestingly, studies on humans with acute cystitis/urinary infection demonstrate that uropathogenic \emph{E. coli} (UPEC) can thrive in the urothelium as intracellular bacterial colonies resisting host immunity (29), that should be accompanied by increased nucleotide release from epithelial cells (see paragraph above).

We hypothesize that in a subset of OAB patients (\emph{i.e.} those with pyuria \(\geq 10^5\) wbc \(\mu l^{-1}\)) there is increased release of ATP, and other nucleotides, from the urothelium caused by low-grade inflammation, which ultimately results in increased sensory nerve excitation and the enhanced symptoms of OAB. Furthermore, in these patients the low-grade inflammation is associated with intracellular bacteria colonization of the urothelium. Here we investigated our hypothesis using human bladder urothelium obtained using flexible cystoscopy.

**Methods:**

\textbf{Reagents.} Chemical reagents were purchased from Sigma-Aldrich (Poole, UK); with the exception of suramin obtained from Bayer AG (Leverkusen, Germany) and DAPI-containing microscope slide mountant obtained from Vector Labs (Peterborough, UK).
HPLC column and solid phase extraction cartridges were obtained from Phenomenex (Macclesfield, UK).

**Human tissue and urine samples.** All procedures were performed with consent and approval from the Moorfields and Whittington Hospitals Research Ethics Committee (London, UK) and the NHS Research Authority South East Coast (Kent). Informed written consent was obtained from volunteers involved in the study. Bladder biopsies and urine samples were obtained from either the Whittington Hospital Campus, University College London or Medway Maritime Hospital. Bladder biopsies were obtained using a flexible cystoscope under local (or rarely general) anaesthesia. A catheter specimen of urine (CSU) was obtained from female patients and a MSU from male patients and non-OAB controls. Patients with idiopathic OAB were recruited from Incontinence Clinics and non-OAB controls were recruited from the Haematuria Clinic. The inclusion criteria for OAB, reconfirmed at the time of sample collection, were adults aged ≥18 years of either sex with frequency ≥8 per day, urgency with or without urgency incontinence, and the absence of a UTI or severe concomitant urinary tract pathology (e.g. chronic obstruction, catheterisation, neurological disease, prior radiotherapy, anatomical defects, implanted devices, pregnancy, bleeding disorders, and/or anticoagulant therapy). All urine samples obtained were sent for conventional urinalysis and bacteria culture at the time of collection, if a UTI was subsequently identified the sample was retrospectively removed from the study. The inclusion criteria for non-OAB were a single historical episode of microscopic haematuria with no underlying pathology. All OAB and non-OAB patients were additionally investigated for pyuria by trained clinicians as previously described (20); significant pyuria was taken as of ≥10 wbc μl⁻¹ of fresh unspun urine. Thus the following experimental groups were used in this investigation: i) non-OAB controls, ii) OAB patients without pyuria, that is patients with no wbc or with <10 wbc μl⁻¹, and iii) OAB patients with pyuria, that is patients with ≥10 wbc μl⁻¹. Urine was either stored on ice and processed within 1 h (for microscopy) or immediately snap-frozen and kept at -80°C until the time of processing (for HPLC). Bladder biopsies were either immediately transported to the laboratory in ice-cold sterile saline and processed within 1 h of collection or placed in 10% formalin for 48
Prior to histological scrutiny.

**Biopsy histology.** Following 48 h in 10% formalin, biopsy tissue was dehydrated with alcohol and xylene in a vacuum infiltration-processing machine for 12 h. The tissue was then impregnated with paraffin wax. A microtome (Microm HM355S; Thermo Fisher Scientific, Loughborough, UK) was used to cut sections of 6 μm thickness. Slices were placed on a glass slide then dried at 60°C for 10 min. The sections were then stained with H&E to evaluate the morphological characteristics of the tissue. A Leica DM4000B upright light microscope (Wetlar, Germany) was used to image the sections.

**Biopsy ATP release.** A Luciferin Luciferase ATP Bioluminiscence Assay Kit was used to quantify ATP release from intact, live, bladder urothelium according to the manufacturer’s protocol. In brief, the urothelial cell layer was manually isolated from the underlying tissue of the bladder biopsy using fine forceps, scalpel and a dissection microscope (final wet tissue weight being 3.4±0.7 mg [n=33]). Two working solutions containing the luciferin luciferase reagents were made up, one in PBS (phosphate buffered saline [1X] containing [mM]: Na₂HPO₄ [10], KH₂PO₄ [1.8] NaCl [137], KCl [2.7], pH 7.4; Solution-A [isotonic solution]) and one with distilled water (Solution-B; hypotonic solution). The intact urothelial cell layer was then incubated for 1 h in Solution-A (100μl) at 37°C in a 96-well plate (Nunc, Roskilde, Denmark). Basal readings of luminescence were taken after 1 h incubation with the tissue still immersed in Solution-A. Stimulated readings of luminescence (i.e. stretch-evoked ATP release) were taken following the addition of Solution-B (100μl) for 1 min. Where stated, stimulated readings of luminescence were taken over a period of 15 min with 3 min interval recordings to observe degradation of ATP with time. Two ATP standard curves, one in Solution-A (100 μl volume), and the other in Solution-A and Solution-B (50:50, 200 μl volume), in combination with blank wells, were prepared alongside each given experiment with concentrations ranging from 10⁻¹⁰ to 10⁻⁷ M. ATP-evoked luminescence was quantified using a luminometer (Synergy 2, BioTek, Winooski, USA). ATP concentration from samples was calculated
from the ATP standards using linear regression analysis. All data were normalised as nM ATP per 5 mg of wet tissue, and stimulated readings presented following the subtraction of basal readings. In experiments investigating the effect of drugs, the same protocol was followed, allowing a minimum of 5 min for the drugs to take effect before luminescence was read. Parallel standard curves were also run in the presence of drugs to investigate any possible interactions with the luciferin luciferase reaction.

**Biopsy vesicle staining.** Following immediate transport to the laboratory in ice-cold sterile saline, biopsy tissue was placed in PBS (1X) and incubated for 1 h at 37 °C to create resting conditions, or, to imitate stretch conditions (i.e. bladder filling), biopsy tissue was then incubated in hypotonic PBS (0.5X) for 1 min. Both the resting and stretch biopsy tissues were immediately transferred to PFA (4%) for 48 h, before being wax-embedded and sectioned (as above: Biopsy histology). The tissue sections were permeated with a 0.1% Triton X100 solution and incubated with quinacrine (100 µM) for 30 min before being washed with PBS (1X). Sections were mounted with DAPI-containing mountant, and visualised under an inverted confocal microscope using the x63 oil immersion objective (Leica SP5; Wetzlar, Germany). Using ImageJ software, mean fluorescence intensity was measured in all images taken from quinacrine-labelled tissue.

**Biopsy RNA extraction and RT-PCR.** Following immediate transport to the laboratory, in cold sterile saline, the urothelial cell layer was manually isolated from the underlying tissue of the bladder biopsy using fine forceps, scalpel and a dissection microscope. Intact urothelium was homogenised in Tri-reagent and then freeze/thawed in liquid nitrogen followed by chloroform extraction and ethanol precipitation. Precipitated RNA was loaded onto Qiagen RNeasy columns (Qiagen, Crawley, UK) for DNase treatment and further purification. RNA concentration was measured using a spectrometer, Nano N-1000 system (Nanodrop Technologies, Wilmington, USA).

Total RNA (10 ng) from each sample was reverse transcribed in a 20 μl reaction volume using the One-step Quantitect Reverse Transcription Kit (Qiagen, Crawley,
UK) according to manufacturer’s instructions. Primers for P2 receptor subtypes were
designed using Primer 3 Web-software (Whitehead Institute for Biomedical
Research, Cambridge, USA) and manufactured by Eurofins-MWG (Ebersberg,
Germany) (see Appendix for primers and mRNA accession numbers used). The real-
time PCR, based on SyBR green detection, (Qiagen, Crawley, UK) was performed
using a Chromo-4 thermal cycler (Bio-Rad, Hemel Hempstead, UK) with 2 µl total
RNA. Using a standard curve, created by duplicate serial dilutions of standard DNA
(target sequence of interest) over 12 logarithmic orders and the thermal cycler
software the relative concentrations of the target amplicons were determined. In
addition, the standard curve was used to verify the linearity of amplification of each
transcript; \( r^2 > 0.99 \) in all cases. The relative concentrations of target in each run were
expressed as a ratio to the housekeeping gene, GAPDH. All PCR products were
checked for specificity and purity from a melting curve profile created after each run
by the thermal cycler software. Homology of the PCR products was further checked
for size by agarose gel electrophoresis.

Urine sediment immunofluorescence. Fresh urine (50 µl; within 1 h of collection and
stored on ice) was spun onto slides using a cytospin (Sandon Cytospin 4, York, UK) at
800 rpm for 5 min. The deposit was stained with acridine orange (0.5% in Gey’s
solution) for 30 min; previously shown to fluoresce green in the presence of viable
organism DNA after excitation by a laser at 436-490 nm (12, 32). In order to
differentiate extracellular from intracellular bacteria, a crystal violet counter-stain
(0.1% in 150 mM NaCl) was added to quench the fluorescence of extracellular
microorganisms. Images were acquired using an upright fluorescence microscope
(Leica DM4000B, Wetlar, Germany), samples were excited at 488 nm and emitted
light collected with a 505-550 nm band pass filter. On those slides found to have
cells containing bacteria, the deposit was fixed with PFA (4%) for 2 min, then further
treated with anti-Uroplakin III (Santa Cruz Biotechnology Inc; Santa Cruz, USA) for 12
h, a specific marker of urothelial cells (10). Alexa 555 (Invitrogen, UK) was used as a
secondary antibody and incubated for 2 h, after which the slides were mounted with
DAPI-containing mountant. Images were acquired with a confocal microscope (Leica
SP5; Wetlar, Germany) and Z-series processed using Volocity software (Improvision,
Coventry, UK). Alexa-555 and DAPI were excited at 543 nm and 405 nm, and emitted light was collected using a 560 nm long-pass filter and 420 nm long pass filter, respectively.

**Urine nucleotide and nucleoside quantification.** Urine, that had previously been immediately snap-frozen and kept at -80°C, was thawed and sterile filtered through a 0.22 µm membrane prior to HPLC analysis. HPLC analysis was performed as previously described (11). In brief, the samples were then subjected to a solid phase extraction cleaning procedure through Strata-X columns (30 mg/ml; Phenomenex, Macclesfield, UK). Elution was achieved using 25 mM ethanolamine at pH 5.0 and 30% methanol in ethanolamine (pH 5.0). A standard curve was prepared alongside each HPLC experiment consisting of ADP only. Samples (100 µl) were injected into the column (Polar-RP 4 µm 80A 250x4.6 mm, Phenomenex, Macclesfield, UK) and a gradient profile of 2%-30% acetonitrile in phosphate buffer was run for 20 min, with an additional 15 min stabilisation period. Nucleotides and nucleosides were UV-detected at 254 nm and areas measured with the Agilent software (Agilent Technologies, Wokingham, UK). Areas were then adjusted to the SPE cartridge performance and compared against standard curves to obtain the final concentration. Urinary creatinine levels were measured using a commercial test (R&D Systems, Abingdon, UK) as per manufacturer’s instructions to ensure data were comparable.

**Statistical analysis.** All numerical data were assessed for normality using the Kolmogorov-Smirnov test. Significance level was evaluated by two-tailed paired and unpaired t-tests, parametric and non-parametric one-way ANOVA with appropriate post-hoc tests. P values less than 0.05 were considered statistically significant. All data presented as mean±SEM, and n equals number of patients or samples.
**Results:**

Bladder biopsies obtained from patients using flexible cystoscopy have full-thickness intact urothelium. H&E staining of wax-embedded and sliced biopsies obtained using flexible cystoscopy routinely demonstrated intact urothelium of full-thickness in samples of all three experimental groups of patients (i.e. non-OAB [8 of 8 specimens], OAB without pyuria [11 of 13 specimens], and OAB with pyuria [6 of 6 specimens]) (Figure 1A). Morphologically distinct umbrella cells were evident on the luminal side of the urothelium further demonstrating the integrity of the tissue (Figure 1B).

Basal ATP release is significantly greater from urothelium of OAB patients with pyuria. To measure ATP release from microdissected urothelium, we used a luciferin luciferase assay. ATP levels became detectable after 15 min and stabilized at 30-40 min (data not shown) and consequently recordings were taken at 60 min. The subtle increase in concentration of ATP, which stabilized with time, was taken to represent basal (i.e. unstimulated) release of ATP. Basal release of ATP was significantly greater from urothelium of OAB patients with pyuria (78.1±20.6 nM/5 mg of wet tissue [hereafter referred to as simply ‘nM’], n=15, P<0.05) than from non-OAB patients (1.9±1.5 nM, n=9) or OAB patients without pyuria (2.2±1.7 nM, n=33) (Figure 2A). Application of a hypotonic solution, to mimic stretch and thus bladder filling, resulted in substantial, and similar increase in ATP release from the urothelium of all three experimental groups (non-OAB patients, 129±48 nM, n=9; OAB patients without pyuria, 38±18 nM, n=33; OAB patients with pyuria, 268±188 nM, n=15) (Figure 2B). Peak stretch-evoked ATP levels (i.e. the highest concentration of ATP measured following stimulation) was achieved within 1 min irrespective of experimental group (n=18; data not shown). The concentration of ATP decreased during hypotonic insult suggesting degradation by endogenous tissue ATPases. As expected, increasing hypotonicity caused additional ATP release from urothelium (~2-fold with 25% hypotonic buffer, ~10-fold with 50% hypotonic buffer, and ~20-fold with 75% hypotonic buffer). The concentration of ATP released from urothelium following osmotic insult decreased by 51±8% (n=9) and 52±11% (n=9).
after 3 min for samples from non-OAB patients and OAB patients with pyuria, respectively, and levels returned to basal concentrations within 10-12 min in both cases. However, for samples from OAB patients without pyuria, the decrease in concentration of stimulated-ATP release was significantly less after 3 min (26±7%; n=9; P<0.05) and returned to basal concentrations in ~30 min (Figure 2C). The slower rate of stimulated ATP decay seen with urothelium obtained from OAB patients without pyuria was similar to that with urothelium obtained from non-OAB patients in the presence of the ATPase inhibitor ARL 67156 (100 μM; n=5) (Figure 2C); ARL 67156 did not alter the peak concentration of stimulation-evoked ATP release (data not shown). For ATP concentration measurements following stimulation, results obtained using HPLC correlated well with results from the luciferin luciferase assay (data not shown); however it was not possible to use HPLC to measure basal ATP release as, in some cases, concentrations were below the level of accurate quantification using the HPLC technique.

Basal ATP release mechanisms differ from stretch-evoked stimulated release. We pharmacologically investigated the molecular mechanism(s) by which ATP is released (primarily stretch-evoked) from human urothelium obtained from non-OAB patients, OAB patients without pyuria, and OAB patients with pyuria, using a luciferin luciferase assay. Basal ATP release from urothelium of OAB patients with pyuria was significantly inhibited (by 67±9%, n=3) by the P2 receptor antagonist suramin (1 mM) and almost abolished by the hemichannel and gap junction blocker carbenoxolone (CBX, 50μM; n=3), yet, was significantly potentiated (by 74±13%, n=3) by the P2 receptor agonist UTP (1 μM) (Figure 3A). The UTP-evoked potentiation of ATP was subtly inhibited (by ~30 nM, n=3) by co-incubation with CBX (50 μM) and significantly inhibited by co-incubation with suramin (1 mM; P<0.05, n=3), suggesting at least two mechanisms of ATP release (i.e. hemichannel-mediated and downstream P2 receptor-evoked) (Figure 3A and 7A). Botulinum toxin-A (BTX-A; 20 units/ml) known to inhibit vesicular release of ATP, brefeldin-A (BFA; 20 μM) known to inhibit vesicular trafficking, capsazepine (3 μM) a blocker of stretch-activated TRP channels, and 4,4'-diisothiocyano-2,2'-stilbenedisulfonic acid (DIDS, 100 μM) a
calcium-activated chloride channel blocker, did not significantly alter basal ATP release (all n=3-4) (Figure 3A). Unfortunately, basal ATP release, as opposed to stretch-evoked ATP release, from urothelium of non-OAB patients and OAB patients without pyuria could not be fully investigated due to barely detectable levels of ATP (see Figure 2A). However, the effects of UTP (1 μM, n=3) were investigated in these tissues and found not to significantly increase basal ATP concentration. Stretch-evoked ATP release (i.e. release evoked by a hypotonic stimulus) from urothelium of OAB patients with pyuria was significantly inhibited (by 72±14%, n=5) by suramin (1 mM; P<0.05) and almost abolished by BTX-A (20 units/ml, n=3) and BFA (20 μM, n=3), but unaffected by capsazepine, CBX, DIDS or UTP (n=3-5) (Figure 3B). Stimulated ATP release from urothelium of non-OAB patients and OAB patients without pyuria, in addition to being abolished by suramin, BTX-A and BFA, was significantly inhibited by capsazepine (by 67±11% [n=3] control and 83±8% [n=4] OAB-pyuria; P<0.05).

Given that BTX-A abolished hypotonicity-evoked ATP release from urothelium of OAB patients with pyuria (Figure 3B) we investigated whether vesicles were evident in the urothelium. Quinacrine staining of wax-embedded and sliced biopsies demonstrated ATP-containing vesicular structures throughout the urothelium and in underlying tissue (Figure 4A). Hypotonic challenge of biopsies from OAB patients with pyuria prior to wax embedding and slicing resulted in significantly less dense quinacrine staining (3.9±1.3 arbitrary units [AU], n=3, as compared to 0.9±0.3 AU, n=3), suggesting vesicle emptying following hypotonic stimulation (Figure 4B), which was inhibited by the addition of BTX-A (1.3±1.3 AU, n=3).

**Altered expression of P2 receptor mRNA in bladder urothelium of OAB patients.** To quantify the relative abundance of P2 receptor mRNA in microdissected urothelium of non-OAB patients, OAB patients without pyuria, and OAB patients with pyuria, we calculated a ratio of the P2 receptor gene of interest to a constitutively expressed housekeeping gene (GAPDH) using RT-PCR.

We failed to detect significant levels (i.e. >5 arbitrary units) of P2X4 and P2Y4 mRNA in urothelium from any experimental group. In contrast, significant amounts
of mRNA were detected for P2X1, 2, 3, 5, 6 and 7, and P2Y1, 2, 6, 11, 12, 13, 14 in urothelium of non-OAB controls; order of expression: P2Y14 >> P2X1, 3, 5, 6 and 7 = P2Y1, 6, 11, 12 and 13 > P2X2 = P2Y2 (Figure 5). Urothelium from OAB patients without pyuria showed a significant increase in abundance of P2Y11 and 13 mRNA (by 200-fold and 10-fold, respectively; n=6; P<0.01). Whereas, urothelium from OAB patients with pyuria showed a significant increase in abundance of P2Y2 and 11 mRNA (100-fold and 50-fold, respectively; n=6; P<0.01) (Figure 5B).

Intracellular bacteria in shed urothelial cells of OAB patients with pyuria. To investigate whether intracellular bacteria are responsible for increased basal release of ATP from urothelium from OAB patients with pyuria we stained cytospun fresh urine samples with acridine orange and crystal violet. Biopsy tissue was not used in this part of the investigation given its precious nature and the necessity of its use in mechanistic luciferin luciferase studies. Planktonic bacteria were observed in 1 of 16 samples from non-OAB patients, whereas, intracellular bacteria were not observed in any sedimentary cells (8±2 urothelial cells per sample, n=16) (Figure 6A). Similarly, planktonic bacteria were observed in <10% of samples from OAB patients without pyuria (n=33) and intracellular bacteria were not observed in any sedimentary cells (Figure 6B). The number of sedimentary cells identified as urothelial cells in urine samples from OAB patients without pyuria was 15±3 (n=33). Planktonic bacteria were observed in 9 of 16 samples from OAB patients with pyuria, and intracellular bacteria were observed in sedimentary urothelial cells from 13 samples (19±3 urothelial cells per sample, n=16). In the 13 samples, 52±9% of urothelial cells were found to contain intracellular bacteria (Figure 6C). To confirm that the cells containing intracellular bacteria were urothelial cells, the deposit was fixed with PFA (4%) then further treated with anti-Uroplakin III (UP-III) and DAPI. In all cases, those cells initially identified as urothelial cells by their morphology alone, were confirmed as urothelial cells by positive UP-III immunofluorescence. Z-stack images obtained by confocal microscopy further confirmed the intracellular localization of bacteria (Figure 6D).
Urinary AMP and adenosine levels are elevated in OAB. Given that basal ATP release is significantly greater from urothelium of OAB patients with pyuria we investigated whether this was detectable by HPLC in MSU samples, as well as other nucleotides (ADP, AMP, GTP, GDP, GMP, UTP, UDP and UMP) and nucleosides (adenosine, guanosine and uridine) that may be altered (Table 1). Urinary AMP levels were significantly greater in samples from OAB patients without pyuria (14.4±8.3 μM, n=17, P<0.05) and OAB patients with pyuria (8.5±2.3 μM, n=16, P<0.05) than non-OAB patients (2.7±0.5 μM, n=11). In addition, urinary adenosine levels were significantly greater in samples from OAB patients without pyuria (228±106 μM, n=17, P<0.05) than non-OAB patients (61±58 μM, n=11). Nucleotide and nucleoside release from biopsy tissue was not investigated using HPLC given the necessity of the tissue’s use in mechanistic luciferin luciferase studies.
**Discussion:**

The main findings of this investigation revealed that basal release of ATP from the urothelium is significantly greater for human OAB patients with pyuria ≥10 wbc μl⁻¹ than for OAB patients without pyuria (or with pyuria <10 wbc μl⁻¹) or non-OAB patients, which may account for the heightened symptoms seen in these patients (36). More specifically, we present evidence that (1) bacteria reside in some urothelial cells of OAB patients with pyuria ≥10 wbc μl⁻¹, and (2) a sequential signaling mechanism occurs whereby (i) basal ATP release from the urothelium is via hemichannels, (ii) ATP released through hemichannels acts in an autocrine/paracrine manner by activating P2 receptors expressed throughout the urothelium (likely to be the P2Y₂ subtype, shown here to be upregulated in OAB patients with pyuria), and (iii) P2 receptor activation causes yet further ATP release from the urothelium via an undetermined mechanism. Taken together, these findings lead to the proposal that in a subset of OAB patients (i.e. OAB patients presenting with pyuria ≥10 wbc μl⁻¹), there is heightened basal ATP release from, and increased P2 receptor expression in, the urothelium originating from intracellular bacteria colonization, that culminates in inappropriate sensory nerve excitation and the symptoms of OAB seen in these patients (see Figure 7A).

In addition to reporting altered urothelial ATP release from OAB patients presenting with pyuria, we also describe stretch-evoked ATP signaling in human urothelium (which does not significantly differ between OAB patients without pyuria, OAB patients with pyuria, and non-OAB patients). Specifically we present evidence that a sequential signaling mechanism occurs whereby (i) urothelial cell stretch (as occurs in bladder filling) evokes vesicular ATP release, (ii) ATP released from vesicles acts in an autocrine/paracrine manner by activating P2 receptors (of which a variety and abundance are expressed throughout the urothelium), and (iii) P2 receptor activation causes yet further vesicular ATP release from the urothelium to presumably activate P2X receptors on suburothelial sensory nerves and therefore signal bladder fullness (see Figure 7B).

**Mechanisms of urothelial ATP release.**
It is well established that extracellular nucleotide signaling arising from the urothelium is important in the regulation of bladder function (3, 8). However, to date little work has been performed on human urothelium. This, in part, is because of the reported fragility of the urothelial cell layer and superficial umbrella cells, and, the logistic difficulty in obtaining tissue samples using the cold-cup biopsy technique (normally performed under general anaesthesia). However, here we demonstrate that full-thickness intact urothelium obtained using flexible cystoscopy, a routinely used procedure using a fibre optic instrument and not requiring general anesthesia of the donor, can be used successfully to study the physiology/pathophysiology of the urothelium \textit{in vitro}.

Using urothelium samples, obtained by flexible cystoscopy, we have presented evidence for an autocrine/paracrine ATP signaling mechanism in human urothelium that presumably culminates in sensory nerve excitation (see Figure 7). Our proposed mechanisms of autocrine/paracrine ATP signaling are broadly in keeping with others. Autocrine/paracrine signaling by ATP, and other nucleotides, in epithelial tissues is a well documented phenomenon, especially in renal tissue where basal ATP release and stretch-evoked ATP release (a function of tubular flow rate) influence ion and water transport mechanisms, and may even influence intrarenal blood flow (21, 35, 39, 60). With respect to the bladder, the group of Birder was the first to propose that the abundance, and variety, of P2 receptors expressed throughout the urothelial cell layer might serve to amplify stretch-evoked ATP signaling (15). Non-neuronal cellular release mechanisms of ATP are not well understood. Proposals to date involve a number of complementary pathways that include transport via ATP-binding-cassette (ABC) proteins, connexin hemichannels, large-diameter anion channels and exocytotic vesicular release (1, 31). Our data using human urothelium demonstrate ATP release via hemichannels and vesicles (see Figure 3 and 4). This investigation extends findings of earlier studies using urothelium by demonstrating multiple, and different, release mechanisms for both basal release (in OAB patients with pyuria) and stretch-evoked release (from all experimental groups). However, disappointingly we report at least one unidentified ATP release mechanism in OAB patients with pyuria that is insensitive to all blockers/antagonists tried (see Figure 7). It is perhaps prudent to mention at this
juncture that the effect of bacteria on urothelial cell permeability has not be
investigated, which of course may also account for increased increased basal release
of ATP from the urothelium of patients with OAB and pyuria.

Current OAB therapies include antimuscarinic and/or BTX-A treatment. The
former is associated with severe side-effects and high rates of withdrawal, and the
latter is notoriously expensive. Our study tested the ability of suramin and BTX-A to
alter the ATP signaling cascades seen in urothelium from OAB patients. Suramin,
successfully inhibited the exaggerated basal ATP release unique to OAB patients with
pyuria, whereas BTX-A was without effect (see Figure 3A). However, stimulated ATP
release, similar in non-OAB patients and OAB patients alike, was inhibited by both
suramin and BTX-A (see Figure 3B). These findings suggest that BTX-A may not be a
suitable therapy for those suffering from OAB with pyuria, and that selective
targeting of urothelial ATP receptors may be an alternative pharmacological strategy
to currently used antimuscarinics in the treatment of OAB (irrespective of pyuria
status).

P2 receptor expression in urothelium.
Using real-time-PCR, we molecularly characterized the P2 receptor subtypes
expressed in urothelium of non-OAB patients, OAB patients without pyuria, and OAB
patients with pyuria. We consistently demonstrated mRNA expression of P2X1-3 and
5-7 receptor subunits, but not P2X4, in samples from all 3 experimental groups. The
level of expression for each subtype did not significantly differ between
experimental groups. Given the ability of P2X receptors to form homomeric and
heteromeric ion channels, the possibility exists that up to 10 subtypes of P2X
receptor (P2X1, 2, 3, 5, 6, 7, 1/2, 1/5, 2/3 and 2/6) may be functionally expressed in
human urothelium. For P2Y receptors, we consistently demonstrated mRNA
expression for all subtypes (P2Y1, 2, 6 and 11-14) with the exception of P2Y4. However,
levels of P2Y2, 11 and 13 were significantly increased in OAB patients, with an increase in
P2Y2 being specific to OAB patients with pyuria and P2Y13 being specific to OAB
patients without pyuria (see Figure 5).

Our PCR findings demonstrating expression of almost all P2 receptors in
human urothelium are broadly in accordance with previous studies that collectively
reported all P2X (P2X1-7) and P2Y1, 2, 4, 6 and 11 localization/expression in native urothelium of human, rat, mouse, rabbit, guinea-pig and cat and in a human urothelial cell line (UROtsa cells) (4, 6, 13-15, 18, 19, 24, 40, 42, 50, 57, 61). That others have not demonstrated P2Y12-14 expression is perhaps due to the recent discovery and cloning of these subtypes from human tissue. Our PCR investigation also extends findings of earlier studies in which P2 receptor expression in the urothelium is described for both human and feline IC patients, whereby P2X1 and 3 and P2Y2 are decreased (6, 15).

Interestingly, stimulation of some P2 receptors (P2X2, 4 and 7, and P2Y6) results in the release of key proinflammatory cytokines (e.g. IL-1β, IL-6, IL-8 and TNFα) (3, 47). IL-1, IL-6 and IL-8 have been shown to presage UTI symptoms (27, 53). Here we present data suggesting that P2Y6 expression may be increased (not quite significant; Figure 5B) in the urothelium of OAB patients with pyuria, which may be critical to the release of these cytokines, and amplify the cascade of events leading to the heightened symptoms of OAB.

Bacterial colonization of bladder urothelium.

With our findings in mind, the most apposite series of animal experiments have been reported by the Hultgren group (41, 59). Using a murine model of chronic urinary infection, they demonstrated the ability of E. coli to colonize the superficial urothelium forming intracellular bacterial colonies (IBCs). These colonies exhibit a reduced susceptibility to antibiotics and host immune mechanisms. Electron microscopy studies showed that colonies formed pod-like protrusions from the cell wall, with the resident bacteria encased in a polysaccharide-rich matrix surrounded by a protective shell. Eventually, bacteria detached from the pod and burst into the bladder lumen where the escaped bacteria then infected fresh cells. However, in this study we failed to identify bacteria residing within the urothelial cells lining the bladder (i.e. in biopsy material) but instead bacteria were identified inside shed urothelial cells found in urine samples. The possibility exists that the shed umbrella cells were from the renal pelvis, ureters, urethra and bladder; although unlikely given that the urine was obtained by CSU sampling.
Interestingly, Rosen and colleagues have published data that showed IBCs forming in urothelial cells of patients with acute cystitis (60). UPEC lipopolysaccharide (LPS) is an extremely potent activator of innate immune responses acting via binding to CD14 and Toll like receptors in the bladder urothelium to activate p38 MAP kinase, Ca$$^{2+}$$ and cAMP signalling which in turn triggers IL-6 and IL-8 production. (34, 56). Furthermore, ATP released from both UPEC and infected cells can stimulate IL-8 production via P2 receptor signalling (4, 43, 55). IL-6 is associated with activation of the acute phase response, which increases production of C-reactive protein from the liver and IL-8 acts as a chemotactic factor for neutrophils (pyuria). The presence of pyuria in the absence of infection (determined by failure to isolate $\geq 10^5$ colony forming units) in a subset of OAB patients, which suggests bladder infection and IBC, is a relatively recent discovery (44).

**Urinary nucleotides and nucleosides as biomarkers of OAB.**

Previous studies have utilized the luciferin luciferase assay to investigate the potential for urinary ATP concentration to serve as a suitable biomarker for UTIs. These studies report ATP concentrations of 5-25 nM in MSU samples collected from patients testing negative for UTIs, and 112-140 nM for patients with positive culture (26, 38), suggesting that ATP could be a biomarker for urinary infection. However, a more recent study looking at ATP concentrations in the urine of OAB patients found similar low levels of ATP in both OAB and non-OAB control groups (1.5 and 1.4 nM [normalized to creatinine concentrations], respectively) (33). Using a novel HPLC technique we found significantly higher levels of AMP in MSU samples from OAB patients (irrespective of pyuric status) than in samples from non-OAB patients. In addition, we detected elevated adenosine in OAB patients without pyuria. Whereas these data are currently too preliminary to propose biomarkers for OAB, it may be useful in determining additional signaling mechanisms responsible for the symptoms of OAB.

**Should pyuria inform the diagnosis and treatment of OAB?**
Data presented here raise the question as to whether OAB with pyuria should be classified and treated differently to OAB without pyuria. Considerable overlap already exists between OAB and chronic prostatitis or “chronic pelvic pain syndrome” and IC, also called “painful bladder syndrome”, and in all cases the diagnosis, rightly or wrongly, relies on exclusion of urinary infection by routine culture methods (54). Our findings suggest that OAB with pyuria has a subclinical UTI component (intracellular bacteria in the urothelium), not dissimilar to recent findings for IC yet without pain and inflammation (29). That significant basal ATP release is novel to OAB with pyuria suggests treatment could be designed accordingly. Further multi-centre investigations are required to fully answer this question; which may need to wait until routine UTI detection methodologies are updated.

**Summary:**

These data provide a better understanding of OAB aetiology and, nucleotide release and signaling in bladder epithelium (in health and disease). The former may prompt clinical re-classification of OAB, to aid successful diagnosis and treatment in the future. The later may help identify alternative, efficacious, and acceptable therapeutic treatments for the unpleasant symptoms of OAB. Conceivably, efficient therapeutic strategies may be evolved to target nucleotide signaling by intravesicular delivery methods to alleviate OAB symptoms and/or treat intracellular bacteria of OAB with pyuria.

**Acknowledgements:**

Supported by grants from the St Peter’s Trust for Kidney, Bladder and Prostate Research (UK), United Kingdom Continence Society (UK), Multiple Sclerosis Society (UK), and East Kent Hospitals University NHS Foundation Trust (UK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:**

The author(s) declare to have no competing interests.
References:


21 Kelley SP, Courtneidge HR, Birch R, Contreras-Sanz A, Kelly MC, Durodie J, Peppiatt-Wildman CM, Farmer CK, Delaney MP, Malone-Lee J, Harber MA,


34 **Moore KH, Malykhina AP.** What is the role of covert infection in detrusor overactivity, and other LUTD? *Neurourol Urodyn* 33(5):606-10. 2014.


43 **Song J, Duncan MJ, Li G, Chan C, Grady R, Stapleton A, et al.** A novel TLR4-


50 **Sui GP, Wu C, Fry CH.** Characterization of the purinergic receptor subtype on guinea-pig suburothelial myofibroblasts. *BJU Int* 97:1327-1331. 2006.


Table 1:

<table>
<thead>
<tr>
<th>Compound</th>
<th>Non-OAB</th>
<th>OAB without pyuria</th>
<th>OAB with pyuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP</td>
<td>1.4±0.8 nM</td>
<td>4.2±3.6 nM</td>
<td>2.0±0.8 nM</td>
</tr>
<tr>
<td>ADP</td>
<td>19.0±8.5 µM</td>
<td>11.7±2.5 µM</td>
<td>24.2±6.5 µM</td>
</tr>
<tr>
<td>AMP</td>
<td>2.7±0.5 µM</td>
<td>14.4±8.3 µM*</td>
<td>8.5±2.2 µM*</td>
</tr>
<tr>
<td>adenosine</td>
<td>61.0±58.5 µM</td>
<td>228±86 µM*</td>
<td>113±42.3 µM</td>
</tr>
<tr>
<td>GTP</td>
<td>44.9±13.9 µM</td>
<td>157±92.7 µM</td>
<td>89.8±42.3 µM</td>
</tr>
<tr>
<td>GDP</td>
<td>128±54.0 µM</td>
<td>83.2±20.0 µM</td>
<td>138±47.3 µM</td>
</tr>
<tr>
<td>GMP</td>
<td>5.5±2.0 µM</td>
<td>20.7±10.3 µM</td>
<td>15.9±6.7 µM</td>
</tr>
<tr>
<td>guanosine</td>
<td>478±174 µM</td>
<td>225±81.5 µM</td>
<td>527±176 µM</td>
</tr>
<tr>
<td>UTP</td>
<td>9.9±2.4 µM</td>
<td>22.9±14.5 µM</td>
<td>8.6±2.6 µM</td>
</tr>
<tr>
<td>UDP</td>
<td>30.6±13.9 µM</td>
<td>20.2±6.3 µM</td>
<td>46.5±19.3 µM</td>
</tr>
<tr>
<td>UMP</td>
<td>1.4±0.6 mM</td>
<td>734±393 µM</td>
<td>667±261 µM</td>
</tr>
<tr>
<td>uridine</td>
<td>7.3±3.4 µM</td>
<td>25.0±8.1 µM</td>
<td>10.0±4.8 µM</td>
</tr>
</tbody>
</table>

Urinary AMP levels are elevated in OAB patients presenting with pyuria. HPLC was used to measure the concentration of nucleotides and nucleosides in urine samples from non-OAB patients, OAB patients without pyuria or with pyuria <10 wbc µl⁻¹ (OAB without pyuria), or with pyuria ≥10 wbc µl⁻¹ (OAB with pyuria). Creatinine levels were similar in all 3 patient groups (non-OAB, 119±25 mg/dl; OAB without pyuria, 132±20 mg/dl; OAB with pyuria, 121±14 mg/dl). Data are mean±SEM (n=11 for non-OAB, n=16 for OAB without pyuria, n=17 for OAB with pyuria). * denotes statistical difference from non-OAB patients (P<0.05).
**Appendix:**

*Human P2 receptor primers and mRNA accession numbers.* Primers were designed using Primer 3 Web software (Whitehead Institute for Biomedical Research, Cambridge, USA) and manufactured by Eurofins-MWG (Ebersberg, Germany).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Accession No.</th>
<th>5’to 3’ Sequence</th>
<th>Position</th>
</tr>
</thead>
</table>
| **P2X1** | NM_002558 | S: CGCCTTCTCTTGGAGATGATGA  
               AS: AGATAAACCCACCTTCTATTAC | 471–491  
               538 – 514 |
| **P2X2** | NM_170682 | S: GCCTACGGGATCCGCATT  
               AS: TGGTGGGAATCAGGCTGAAC | 958 – 975  
               1024– 1005 |
| **P2X3** | NM_002559 | S: GCTGGACCATCGGGATCA  
               AS: GAAAACCCACCTACAAAGTAGGA | 135 – 152  
               205 – 182 |
| **P2X4** | NM_002560 | S: CTCTGCTTGCCAGTACTC  
               AS: CAGGAGATACGGTGCTCAAC | 1108– 1128  
               1176– 1155 |
| **P2X5** | NM_002561 | S: CTGCCGTGCTGTGCTTAC  
               AS: GCAGGGACACCTTCTTGT | 311 – 328  
               378 – 360 |
| **P2X6** | AF065385 | S: AGGCCAGTGTGGTGTTCATC  
               AS: TCTCCACTGGGCACCAACT | 488 – 507  
               555 – 536 |
| **P2X7** | NM_002562 | S: TCTTCGTGATGACAAACTTTCTCAA  
               AS: GTCTCCGCGGTGGGATACT | 401 – 425  
               476 – 458 |
| **P2Y1** | NM_002563 | S: CTGCCGTGCTGGGTGACTT  
               AS: GGACCCCGGTACCTGAGTAGA | 1352 – 1370  
               1419 – 1399 |
| **P2Y2** | NM_176072 | S: GAACCTGACATGCAGAGGATAGA  
               AS: GCCGCCGCTGACCTGAGTAGA | 1495 – 1520  
               1567 – 1551 |
| **P2Y4** | NM_002565 | S: CGTGCTCGCTTGCTGGTTCA  
               AS: GGGCCAGTGTGGTGTTCATC | 725 – 742  
               793 – 776 |
| **P2Y6** | NM_176797 | S: GCCGGCGACCCATGACA  
               AS: GACCCTGCCTCTGCACTTTT | 1171 – 1186  
               1227 – 1209 |
| **P2Y11** | NM_002566 | S: CTGGAGCGCCTTCCTTCTCATC  
               AS: GTAGCCTGCTGGGTGACTT | 511 – 530  
               586 – 567 |
| **P2Y12** | NM_022788 | S: AGGTCCTCTCCCCACTGCTTCA  
               AS: CATCGCCAGCGCCATTGT | 318 – 339  
               385 – 368 |
| **P2Y13** | NM_023914 | S: GAGACACTCGGATAGTACAGCTGGTA  
               AS: GCAGGATCGCGGTGCTCAAGA | 223 – 248  
               291 – 274 |
| **P2Y14** | NM_014879 | S: TTCCTTTCAAGATCCTTGGTGACT  
               AS: GCGAGGAGCCTGCAACACAA | 433 – 456  
               505 – 486 |
**Figure legends:**

**Figure 1.** Bladder biopsies obtained using flexible cystoscopy have full-thickness urothelium. Human bladder biopsies were obtained using a flexible cystoscope under local or general anaesthetic. Biopsies were placed in 10% formalin for 48 h prior to dehydration with alcohol and xylene, and paraffin wax embedding. Sections (6 μm thick) were stained with H&E to investigate urothelium integrity. (A) Representative microphotograph of a biopsy section from an OAB patient that presented with pyuria of <10 wbc μl⁻¹. Full-thickness urothelium is evident in the sample (between arrowheads). (B) Representative microphotograph of a biopsy section from an OAB patient that presented with pyuria of ≥10 wbc μl⁻¹. Full-thickness urothelium is evident in the sample (as in A); umbrella cells lining the luminal membrane are clearly visible (arrowheads). Scale bars equal 200 μm.

**Figure 2.** Greater ATP release from urothelium of OAB patients with pyuria of ≥10 wbc μl⁻¹. ATP release from microdissected urothelium was measured using a luciferin luciferase assay. ATP release was first measured at rest (classified here as ‘basal’ release) and then after addition of a hypotonic solution (to cause cell stretch and mimic bladder filling; classified here as ‘stimulated’ release). Data for stimulated ATP release is presented following subtraction of basal release values. (A) Basal ATP release from urothelium of OAB patients with pyuria ≥10 wbc μl⁻¹ (OAB + pyuria; n=15) was significantly greater than basal ATP release from urothelium of OAB patients without pyuria, or with pyuria <10 wbc μl⁻¹ (OAB - pyuria; n=9), or non-OAB patients (P<0.05; n=9). (B) Stimulated ATP release from the urothelium was not significantly different between experimental groups (non-OAB patients, n=9; OAB patients without pyuria, n=9; OAB patients with pyuria, n=15). (C) The rate at which the concentration of ATP decreased, following stimulation and in the continued presence of hypotonic solution, was greatest from urothelium of non-OAB patients (n=9) and OAB patients with pyuria (n=15). The decreased rate of stimulated ATP degradation seen from urothelium of OAB patients without pyuria (n=9), was similar to that from urothelium of non-OAB patients in the presence of the ATPase inhibitor ARL 67156 (100 μM, n=5). Data shown are mean±SEM. * denotes significant difference from non-OAB, where P<0.05. In (A) and (B) data were compared by using one-way ANOVA and Dunnett’s post-hoc test against non-OAB (the identified control); in (C) data were compared by using two-way ANOVA (time after stimulation being the repeated measures factor, and the between factor being the patient conditions) and Dunnett’s post-hoc test against non-OAB (identified control).

**Figure 3.** Mechanisms of ATP release from urothelium of OAB patients with pyuria. ATP release from microdissected urothelium of OAB patients with pyuria ≥10 wbc μl⁻¹ (OAB + pyuria) was measured using a luciferin luciferase assay. ATP release was first measured at rest (‘basal’) or after addition of a hypotonic solution (‘stimulated’). Data for stimulated ATP release is represented following subtraction of basal release values. Urothelium was pre-treated
with the stated drug for 5 min prior to measuring ATP release (basal or stimulated). (A) Basal ATP release from urothelium was significantly attenuated by both suramin (1 mM, n=3) and carbenoxolone (CBX, 50 μM, n=3), and significantly potentiated by UTP (1 μM, n=3) (P<0.05 in all cases). The potentiating effects of UTP were inhibited by co-treatment with either CBX or suramin. (B) Stimulated ATP release from the urothelium was significantly attenuated by suramin (n=5), botulinum toxin-A (BTX-A, 20 units/ml, n=3) or brefeldin-A (BFA, 20 μM, n=3) (P<0.05 in all cases). Co-treatment of either BFA or suramin with UTP (n=3 in both cases) had no further effect. Data shown are mean±SEM. * denotes P<0.05. In (A) and (B) data were compared by using one-way ANOVA and Dunnett’s post-hoc test against non-OAB (the identified control).

Figure 4. **Urothelial cell stretch evokes vesicular release of ATP.** Human bladder biopsies were obtained using a flexible cystoscope under local anaesthetic. Biopsies were placed in 10% formalin for 48 h prior to dehydration with alcohol and xylene, and paraffin wax embedding. In some cases, biopsies were challenged with a hypotonic solution (to cause cell stretch and mimic bladder filling) prior to fixation. Sections (6 μm thick) were stained with DAPI and quinacrine to investigate localisation of ATP-containing vesicles. (A) Representative microphotograph of a biopsy section from an OAB patient with pyuria ≥10 wbc μl^{-1}; i) DAPI staining (blue), ii) quinacrine staining (green), iii) composite image of DAPI and quinacrine staining, iv) bright field image. ATP containing vesicles are evident throughout the urothelium. (B) Representative microphotograph of a biopsy section from an OAB patient with pyuria ≥10 wbc μl^{-1}, challenged with a hypotonic solution prior to fixation; i) - iv) as above. ATP containing vesicles are less evident throughout the urothelium. Scale bars equal 100 μm.

Figure 5. **Altered P2Y receptor expression in urothelium of OAB patients.** RT-PCR was performed on microdissected urothelium of non-OAB patients, OAB patients without pyuria, or with pyuria <10 wbc μl^{-1} (OAB – pyuria), and OAB patients with pyuria ≥10 wbc μl^{-1} (OAB + pyuria). The ratio of the P2 receptor gene of interest to a constitutively expressed housekeeping gene (GAPDH) was calculated. (A) Ionotropic P2X receptor mRNA levels were similar in urothelium from the three experimental groups (n=6). (B) Urothelium from OAB patients without pyuria showed a significant increase in abundance of metabotropic P2Y_{11,13} mRNA (n=6; P<0.01). Whereas, urothelium from OAB patients with pyuria showed a significant increase in abundance of metabotropic P2Y_{2,11} mRNA (n=6; P<0.01). Data shown are mean±SEM. * denotes significant difference from non-OAB, where P<0.01. In (A) and (B), data were compared by using one-way ANOVA and Dunnett’s post-hoc test against basal or stimulated, respectively (the identified controls).
Figure 6. **Intracellular bacteria identified in shed urothelial cells from OAB patients with pyuria \( \geq 10 \text{ wbc} \mu l^{-1} \).** Fresh urine was spun onto slides using a cytopsin and the deposit stained with acridine orange (which fluoresces green in the presence of viable organism DNA). In order to differentiate extracellular from intracellular bacteria, a crystal violet counter-stain was added to quench the fluorescence of extracellular microorganisms. Images were acquired using an upright fluorescence microscope. Intracellular bacteria were not observed in sedimentary cells from the urine of non-OAB patients (see A for a representative image) or OAB patients without pyuria, or with pyuria <10 wbc \( \mu l^{-1} \) (OAB – pyuria; see B for a representative image). (C) Representative microphotograph of shed urothelial cell colonized by intracellular bacteria (arrow) from an OAB patient with pyuria \( \geq 10 \text{ wbc} \mu l^{-1} \) (OAB + pyuria). Bacterial colonization of urothelial cells was seen in 81% of urine samples tested (n=16), and of those, 52±9% of urothelial cells contained bacteria (19±3 urothelial cells per sample). Further confirmation of the intracellular localisation of bacteria and cell type was obtained by treatment with anti-uroplakin III (red; a marker of urothelial cells) and DAPI (blue; marker of DNA). Images were acquired with a confocal microscope and Z-series processed using Volocity software. (D) Representative 2D microphotograph of three shed urothelial cells from urine of an OAB patient with pyuria (Di), whereby the intracellular localisation of bacteria is evident in the side projections (Dii and Diii; dashed line shows origin of side-projection). Scale bars equal 10 \( \mu m \).

Figure 7. **Proposed mechanisms of ATP release from urothelium of OAB patients with pyuria.** In our investigations, basal release of ATP was \( \sim 15 \)-fold greater from urothelium of OAB patients with pyuria, nearing levels normally associated with stretch and bladder fullness. Histology demonstrates that bacteria reside in urothelial cells, and RT-PCR suggest that levels of P2Y2 and P2Y11 are increased. (A) When the bladder is at rest there is a substantial release of ATP (basal release) from the urothelium, which in our experiments is abolished by CBX, suggesting release via hemichannels (1.). We propose that the released ATP acts in a paracrine/autocrine fashion to activate P2 receptors expressed throughout the urothelium (including the upregulated P2Y2 and P2Y11 subtypes) (2.). P2 receptor activation in turn evokes further ATP release (in our experiments attenuated by suramin and potentiated by UTP) via an undetermined mechanism (3.). Presumably, released ATP reaches levels able to activate P2 receptors expressed on suburothelial sensory nerves, resulting in inappropriate signalling normally associated with bladder fullness (4.). We hypothesise that the presence of intracellular bacteria (IB) is responsible for increased P2 receptor expression and hemichannel mediated ATP release. (B) When the urothelium is stretched (i.e. when the bladder is full) there is a substantial release of ATP (stimulated release), which in our experiments is abolished by BTX-A or BFA, suggesting release from vesicles (1.). We propose that the released ATP acts in a paracrine/autocrine fashion to activate P2 receptors expressed throughout the urothelium (2.). P2 receptor activation in turn evokes further ATP release (in our experiments attenuated by suramin) again from vesicles (3.). Presumably, released ATP reaches
levels able to activate P2 receptors expressed on suburothelial sensory nerves, resulting in signalling of bladder fullness (4.). The presence of intracellular bacteria (IB) does not appear to alter stimulated ATP release from urothelium.
A

ATP release at rest (basal)

B

Stretch-evoked ATP release (stimulated)

C

ATP decay (post stimulation)

- OAB - pyuria
- non-OAB
- (+ ARL67156)
- non-OAB
- OAB + pyuria

Post-stimulation ATP levels (% max)

Time after stimulation (min)
A

B

mRNA ratio
P2X vs. GAPDH (AU)

non-OAB
OAB - pyuria
OAB + pyuria

mRNA ratio
P2Y vs. GAPDH (AU)

non-OAB
OAB - pyuria
OAB + pyuria

*
Key:  , intracellular bacteria;  , hemichannel;  , ATP;  , P2Y receptor;  , undetermined ATP channel;  , P2X receptor;  , ATP-containing vesicle.